You are here: Industry Insights > Heart failure

News List

SGLT-2 inhibitors may primarily drive growth of branded heart failure treatment market: GlobalData expresspharma
September 16, 2020
Approximately 55 per cent of type T2D patients suffer from cardiovascular disease (CVD), which often leads to further complications such as major adverse cardiac events.
Novartis' Entresto racks up a heart failure study win—but it's a mixed one fiercepharma
September 01, 2020
As the bestselling drug in the heart failure space, Novartis' Entresto suffered a stinging setback last year in a novel indication—but there were some signs of hope.
Empagliflozin reduced risk of death and hospitalisation for heart failure by 25 per cent in adults expresspharma
August 31, 2020
Boehringer Ingelheim announced the full results from the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes.
WHF partners with AZ to reduce burden of CV disease pharmatimes
August 26, 2020
AstraZeneca is partnering with the World Heart Federation (WHF) to progress global action to prevent, control and reduce the burden of cardiovascular (CV) disease and its associated risks and complications.
Empagliflozin meets primary endpoint in Phase III heart failure trial expresspharma
July 31, 2020
It reduced the risk of cardiovascular death or hospitalisation for heart failure versus placebo on top of standards of care in adults with heart failure with reduced ejection fraction.
Farxiga Granted Fast Track Designation for Heart Failure Following Acute Myocardial Infarction americanpharmaceuticalreview
July 24, 2020
AstraZeneca has been granted Fast Track Designation in the US for the development of Farxiga (dapagliflozin) to reduce the risk of hospitalization for heart failure (hHF) or cardiovascular (CV) death in adults following an acute myocardial infarction ...
AZ' Farxiga fast-tracked for heart failure following MI pharmatimes
July 20, 2020
AstraZeneca's Farxiga (dapagliflozin) has been granted a Fast Track Designation in the US for reducing the risk of hospitalisation for heart failure (hHF) or cardiovascular (CV) death in adults following an acute myocardial infarction (MI) or heart attack
Astrazeneca’s Dapagliflozin gets DCGI nod for treatment of heart failure expresspharma
July 06, 2020
Dapagliflozin (Forxiga) is an SGLT-2 inhibitor that can reduce the risk of cardiovascular death and hospitalisation for heart failure in patients with HFrEF.
CV patients finding it harder to get treatment during pandemic pharmatimes
June 08, 2020
The British Heart Foundation (BHF) is warning that patients with heart and circulatory conditions are having difficulty in getting treatment during the pandemic.
FDA Grants Fast Track Designation for Omecamtiv Mecarbil in Heart Failure americanpharmaceuticalreview
May 13, 2020
Amgen and Cytokinetics announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for omecamtiv mecarbil.

Previous page 1 2 3 4 5 6 7 Next page